The Sinclair Method (TSM) for the Treatment of Alcoholism. Clinical Research Findings and Best Protocol for Success Updated 2014

Size: px
Start display at page:

Download "The Sinclair Method (TSM) for the Treatment of Alcoholism. Clinical Research Findings and Best Protocol for Success Updated 2014"

Transcription

1 Information for Medical & Treatment Professionals The Sinclair Method (TSM) for the Treatment of Alcoholism Clinical Research Findings and Best Protocol for Success Updated 2014 "One medication, naltrexone, has been identified as a safe and effective treatment for alcohol dependence. - World Health Organization, 1996

2 The Sinclair Method (TSM) for Alcoholism: Using Naltrexone Correctly; Information for Medical & Treatment Professionals Updated 2014 Table of Contents Summary Selected Quotes from Significant Research About Research Findings JAMA Study Abstract Interpretation of Clinical Results Underlined, Italics & Bold Interpreting The Trial Data Trials Involving Naltrexone and/or Nalfamine Forum Naltrexone Clinical Update

3 The Sinclair Method (TSM) for Alcoholism: Using Naltrexone Correctly; Information for Medical & Treatment Professionals Ver: LB Summary In clinical trials, where Alcohol was combined with naltrexone or nalmefene, 90 out of 91 clinical trials found significant benefits. Craving, drinking levels, relapse levels and liver damage markers were found to decrease over time. (A list of all trials and their conclusions are included at the end of this booklet). Where Alcohol was NOT combined with naltrexone or nalmefene, 36 out of 37 trials found no significant benefits. Trials proved that naltrexone only worked when it is taken either just prior to drinking alcohol or during drinking. This is due to the mechanism of the drug, which relies on pharmacological extinction. Naltrexone, available in generic form in the United States and Canada, has been approved by the FDA since It is non-addictive and will cause few, if any adverse side-affects. Naltrexone can be prescribed by a family doctor, without additional requirement for counselling or psychological therapy. The Sinclair Method (TSM) protocol is as follows: The recommended dose for patients is 50mg to be taken one (1) hour before drinking. Patients may start naltrexone while intoxicated without adverse affect. No detoxification prior to treatment is required. Naltrexone is often prescribed incorrectly (without drinking). If used this way it will be no more effective than placebo. The Sinclair Method advises against using naltrexone during periods of abstinence. When patients are directed to take naltrexone according to the TSM protocol (one hour before drinking, and not on days when no drinking occurs) chances of success are greatest: 75% success rate in Finnish clinics; 85% in Florida clinics and 75% success rate in the NGO (CORD) trial in India have been documented. The NationaI Institute on Alcohol Abuse & Alcoholism (NIAAA) and the World Health Organization (WHO) estimate that current rehabilitation methods (including AA, CBT, long-term rehabilitation programs and other common non-pharmacological treatment methods) yield success rates of around 10-15%.

4 The Sinclair Method (TSM) for Alcoholism: Using Naltrexone Correctly; Information for Medical & Treatment Professionals Ver: LB Selected Quotes from Significant Research (Full Citation for All Research is Listed at the Back of this Document) "One medication, naltrexone, has been identified as a safe and effective treatment for alcohol dependence. (World Health Organization, 1996) "Of all drugs studied for the treatment of alcohol dependence, the evidence of efficacy is strongest for naltrexone... (New England Journal of Medicine, 1999) "Significant benefits of naltrexone are still present three years after start of treatment in patients always taking medication before drinking, on craving, drinking levels, and liver damage markers. (Alcoholism: Clinical and Experimental Research, 2000) "Naltrexone significantly better than placebo: lack of relapse to heavy drinking = 90% in naltrexone group vs. 61.4% (or 11.4% reported online) with placebo. (Journal of Addictive Diseases, 2000) "Naltrexone was safe and effective, especially with a high craving and a family history of alcoholism. (American Journal of Addiction, 2001) "Naltrexone may be of benefit to women who are unable to maintain total abstinence from alcohol...among those drinking, naltrexone significantly delayed the time to the second relapse and the time to the third relapse. (Alcoholism: Clinical and Experimental Research, 2008) Naltrexone reduced drinking days and heavy drinking days, plus craving in early onset drinkers and time between drinks in patients with more alcoholic relatives. (Alcoholism: Clinical and Experimental Research, 2008) "Naltrexone has been safe and effective, with a 75% success rate, when introduced in northern India with an extinction protocol including no prior detox and instruction to take naltrexone always before drinking but only when drinking is expected. (Proceedings of the Annual Meeting of the International Society on Addiction Medicine (ISAM), 2009)

5 The Sinclair Method (TSM) for Alcoholism: Using Naltrexone Correctly; Information for Medical & Treatment Professionals Updated 2014 About Research Findings

6 The Sinclair Method (TSM) for Alcoholism: Using Naltrexone Correctly; Information for Medical & Treatment Professionals Updated 2014 About Research Findings.Continued

7

8 The Sinclair Method (TSM) for Alcoholism: Using Naltrexone Correctly; Information for Medical & Treatment Professionals Updated 2014 Interpretation of Clinical Trial Results: Trials Involving Naltrexone and/or Nalfamine SUMMARY OF RESEARCH FINDINGS: When extinction was possible, 90 out of 91 clinical trials found significant benefits from the opioid antagonist. When extinction was not possible, 36 out of 37 trials found no significant benefits from the opioid antagonist. (Source: Dr. R. Eskapa, PhD; Dr. D. Sinclair, PhD DEFINITION of EXTINCTION : Extinction, refers to Pharmacological Extinction. Pharmacological extinction works on the premise that Alcohol Dependence is a form of Pavlovian conditioning. When people drink alcohol, endorphins are released into the brain, and this reinforces the behavior of drinking alcohol. Naltrexone blocks these endorphins from binding to the brain's receptors and the alcohol drinking behavior is extinguished. When extinction is possible means: Where taking the opioid blocker, such as Naltrexone or Nalmefene, WITH alcohol was possible as part of the study. When extinction was not possible means: Taking the opioid blocker WITHOUT alcohol (example: Naltrexone AND Abstinence from Alcohol) was part of the study. KEY CONCLUSION: Where Alcohol was combined with Naltrexone or Nalmefene, 90 out of 91 clinical trials found significant benefits. Where Alcohol was NOT combined with Naltrexone or Nalmefene, 36 out of 37 trials found no significant benefits.

9 The Sinclair Method (TSM) for Alcoholism: Using Naltrexone Correctly; Information for Medical & Treatment Professionals Updated 2014 Key: Underlined, Italics & Bold How to Interpret The Trial Data on the Following Pages

10 The Sinclair Method (TSM) for Alcoholism: Using Naltrexone Correctly; Information for Medical & Treatment Professionals Updated 2014 Trials Involving Naltrexone and/or Nalfamine Trials Continued on Next Page NOTES:

11 Trials Involving Naltrexone and/or Nalfamine

12

13

14 Trials Involving Naltrexone and/or Nalfamine cont.

15

16

17

18

19

20

21

22

23 Source: Dr. R. Eskapa, PhD; Dr. D. Sinclair, PhD

24

25 NOTES:

What happens if i drink on naltrexone

What happens if i drink on naltrexone +18 Seks Video XXX Sikiş Porno izle Search... Search Sort: Date View: Sort Ascending What happens if i drink on naltrexone saw & tig. For Alcohol Dependence: "I am using naltrexone per The Sinclair Method

More information

Naltrexone protocol alcohol

Naltrexone protocol alcohol P ford residence southampton, ny Naltrexone protocol alcohol The premier alcohol treatment program. Control or eliminate alcohol use using the Sinclair Method A Non 12-Step Outpatient Program. If you would

More information

THE NALTREXONE CHALLENGE

THE NALTREXONE CHALLENGE THE NALTREXONE CHALLENGE DISCLOSURE Natasha Rodney-Cail, Pharmacist, Drug Evaluation Unit Has no conflicts of interest Maureen Allen Has no conflicts of interest DONNA 68 years old Currently treated with

More information

Can you drink on naltrexone

Can you drink on naltrexone Can you drink on naltrexone Search 1-9-2000 Naltrexone is a medicine that can help people with alcoholism to stop drinking alcohol. It also helps people addicted to opioids. 15-4-2009 Before he found naltrexone,

More information

The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines

The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines Background, Objectives and Methods Systematic reviews (SRs) published by Cochrane Drugs

More information

Medication Assisted Treatment of Substance Use Disorders

Medication Assisted Treatment of Substance Use Disorders 3 rd Annual Challenges & Innovations in Rural Psychiatry Conference Medication Assisted Treatment of Substance Use Disorders June 22, 2016 Medication Assisted Treatment of Substance Use Disorders Richard

More information

Pharmacotherapy of Alcohol Use Disorders

Pharmacotherapy of Alcohol Use Disorders Pharmacotherapy of Alcohol Use Disorders Roger D. Weiss, MD Professor of Psychiatry, Harvard Medical School Chief, Division of Alcohol and Drug Abuse McLean Hospital rweiss@mclean.harvard.edu Consultant

More information

OPIOID ANTAGONISTS IN THE TREATMENT OF ALCOHOL DEPENDENCE: CLINICAL EFFICACY AND PREVENTION OF RELAPSE

OPIOID ANTAGONISTS IN THE TREATMENT OF ALCOHOL DEPENDENCE: CLINICAL EFFICACY AND PREVENTION OF RELAPSE Alcohol & Alcoholism, Vol. 31, Suppl. 1, pp. 77-81, 1996 OPIOID ANTAGONISTS IN THE TREATMENT OF ALCOHOL DEPENDENCE: CLINICAL EFFICACY AND PREVENTION OF RELAPSE STEPHANIE S. O'MALLEY Department of Psychiatry.

More information

Addiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer

Addiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer Addiction to Opioids Marvin D. Seppala, MD Chief Medical Officer Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice Friday, September 30, 2016 26 y.o. female from South

More information

Arwen Podesta, MD. ABIHM, ABAM, Forensic Psychiatry

Arwen Podesta, MD. ABIHM, ABAM, Forensic Psychiatry The State of Medicine in Addiction Recovery Arwen Podesta, MD ABIHM, ABAM, Forensic Psychiatry www.podestawellness.com 504-252-0026 http://www.addictionpolicy.org/ Overview Addiction is a serious, chronic

More information

If gambling treatment was evidence based, what would it look like?

If gambling treatment was evidence based, what would it look like? If gambling treatment was evidence based, what would it look like? Professor Mark Griffiths International Gaming Research Unit Nottingham Trent University E-mail : mark.griffiths@ntu.ac.uk Website :http://ess.ntu.ac.uk/griffiths

More information

BASIC VOLUME. Elements of Drug Dependence Treatment

BASIC VOLUME. Elements of Drug Dependence Treatment BASIC VOLUME Elements of Drug Dependence Treatment Module 3 Principles of CBT and relapse prevention strategies Introduction to Cognitive Behavioural Therapy Basics of pharmacological treatment Workshop

More information

Medication Assisted Treatment: Right for you, Right for your Recovery? Robert Matylewicz, DO, FASAM Medical Director, Clarity Way Inc.

Medication Assisted Treatment: Right for you, Right for your Recovery? Robert Matylewicz, DO, FASAM Medical Director, Clarity Way Inc. Medication Assisted Treatment: Right for you, Right for your Recovery? Robert Matylewicz, DO, FASAM Medical Director, Clarity Way Inc. Elements Behavioral Health Diplomate, American Board of Addiction

More information

Medication Assisted Treatment for Opioid Use Disorders and Veteran Populations

Medication Assisted Treatment for Opioid Use Disorders and Veteran Populations Medication Assisted Treatment for Opioid Use Disorders and Veteran Populations Kamala Greene Genece, Ph.D. VP, Clinical Director Phoenix Houses of New York Benjamin R. Nordstrom, M.D., Ph.D. President

More information

THE STATE OF MEDICINE IN ADDICTION RECOVERY

THE STATE OF MEDICINE IN ADDICTION RECOVERY OVERVIEW: Review addiction stats and trends Define addiction Explain neurobiology of addiction Review treatments of addiction Addiction Definition: A Primary, chronic, relapsing disease of brain reward,

More information

Buprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction

Buprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction Buprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction The Problem The overdose death rate in Missouri and in the country has been rising for

More information

Buprenorphine as a Treatment Option for Opioid Use Disorder

Buprenorphine as a Treatment Option for Opioid Use Disorder Buprenorphine as a Treatment Option for Opioid Use Disorder Joji Suzuki, MD Assistant Professor of Psychiatry Harvard Medical School Director, Division of Addiction Psychiatry Brigham and Women s Hospital

More information

Health Systems and Addiction: Provider Issues

Health Systems and Addiction: Provider Issues Health Systems and Addiction: Provider Issues The Emerging Roles of Primary Care Patrick G. O Connor MD, MPH Dan and Amanda Adams Professor of General Medicine Chief, General Internal Medicine Yale University

More information

Treating Addiction as a Chronic Illness: Why it is Finally Possible. A. Thomas McLellan Treatment Research Institute

Treating Addiction as a Chronic Illness: Why it is Finally Possible. A. Thomas McLellan Treatment Research Institute Treating Addiction as a Chronic Illness: Why it is Finally Possible. A. Thomas McLellan Treatment Research Institute 9/29/2014 Treatment Research Research Institute, Institute, 20132012 The End Because

More information

Long term treatment for opioid dependence Antagonist therapy

Long term treatment for opioid dependence Antagonist therapy Long term treatment for opioid dependence Antagonist therapy Treatment of Opioid Dependence Antagonist treatment Naltrexone Naltrexone (NTX) synthesized in 1965 Eliminate drug carving and prevent relapse

More information

ALCOHOL USE DISORDER WITHDRAWAL MANAGEMENT AND LONG TERM TREATMENT ANA HOLTEY, MD ADDICTION MEDICINE FELLOW UNIVERSITY OF UTAH HEALTH

ALCOHOL USE DISORDER WITHDRAWAL MANAGEMENT AND LONG TERM TREATMENT ANA HOLTEY, MD ADDICTION MEDICINE FELLOW UNIVERSITY OF UTAH HEALTH ALCOHOL USE DISORDER WITHDRAWAL MANAGEMENT AND LONG TERM TREATMENT ANA HOLTEY, MD ADDICTION MEDICINE FELLOW UNIVERSITY OF UTAH HEALTH Prevalence of 12-Month Alcohol Use, High-Risk Drinking, and DSM-IV

More information

6/6/2018. Objectives. Outline. Rethinking Medication Treatment for Opioid Use Disorder

6/6/2018. Objectives. Outline. Rethinking Medication Treatment for Opioid Use Disorder Rethinking Medication Treatment for Opioid Use Disorder International Conference on Opioids June 10, 2018 Dustin Patil, MD Fellow, Addiction Psychiatry Boston Medical Center John Renner, MD Professor of

More information

Management Options for Opioid Dependence:

Management Options for Opioid Dependence: Management Options for Opioid Dependence: Policy Implications and Recommendations Dan Ollendorf, PhD Sarah Jane Reed, MSc New England CEPAC Goal: To improve the application of evidence to guide practice

More information

Biological Addictions Treatment. Psychology 470. Many Types of Approaches

Biological Addictions Treatment. Psychology 470. Many Types of Approaches Many Types of Approaches Biological Addictions Treatment Psychology 470 Introduction to Chemical Additions Steven E. Meier, Ph.D. Listen to the audio lecture while viewing these slides Detoxification approaches

More information

Treatment Alternatives for Substance Use Disorders

Treatment Alternatives for Substance Use Disorders Treatment Alternatives for Substance Use Disorders Dean Drosnes, MD, FASAM Associate Medical Director Director, Chronic Pain and SUD Program Caron Treatment Centers 1 Disclosure The speaker has no conflict

More information

Foundations of Addictions

Foundations of Addictions Foundations of Addictions Week 8 Glenn Maynard, LPC Addiction as a maladaptive behavior This approach is grounded in psychology Model comes from classical conditioning, operative conditioning and social

More information

METHADONE TO BUPRENORPHINE TRANSFERS TRANSITIONING FROM METHADONE MAINTENANCE TO BUPRENORPHINE/NALOXONE

METHADONE TO BUPRENORPHINE TRANSFERS TRANSITIONING FROM METHADONE MAINTENANCE TO BUPRENORPHINE/NALOXONE METHADONE TO BUPRENORPHINE TRANSFERS TRANSITIONING FROM METHADONE MAINTENANCE TO BUPRENORPHINE/NALOXONE Work with methadone clinic staff to coordinate the methadone taper, with the transition to buprenorphine/naloxone:

More information

Opioid Use Disorder Treatment Initiation in Diverse Settings

Opioid Use Disorder Treatment Initiation in Diverse Settings Opioid Use Disorder Treatment Initiation in Diverse Settings Sarah Wakeman, MD, FASAM Medical Director, Mass General Substance Use Disorder Initiative Assistant Professor, Harvard Medical School Disclosures

More information

Medication-Assisted Treatment. What Is It and Why Do We Use It?

Medication-Assisted Treatment. What Is It and Why Do We Use It? Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite

More information

Screening, Diagnosis, and Medication Assisted Treatment for Alcohol Use Disorders

Screening, Diagnosis, and Medication Assisted Treatment for Alcohol Use Disorders Psychiatry and Addictions Case Conference Screening, Diagnosis, and Medication Assisted Treatment for Alcohol Use Disorders MARK DUNCAN, MD Acting Assistant Professor, Co-lead University of Washington

More information

An Internist s Guide to Unhealthy Alcohol Use. Ryan Graddy, MD JHU SOM

An Internist s Guide to Unhealthy Alcohol Use. Ryan Graddy, MD JHU SOM An Internist s Guide to Unhealthy Alcohol Use Ryan Graddy, MD JHU SOM Disclosures None Learning Objectives Understand the terminology used to describe unhealthy alcohol use Identify means of screening

More information

Agenda. 1 Opioid Addiction in the United States. Evidence-based treatments for OUD. OUD Treatment: Best Practices. 4 Groups: Our Model

Agenda. 1 Opioid Addiction in the United States. Evidence-based treatments for OUD. OUD Treatment: Best Practices. 4 Groups: Our Model Agenda 1 Opioid Addiction in the United States 2 Evidence-based treatments for OUD OUD Treatment: Best Practices 4 Groups: Our Model 2 Groups is a national network of clinics providing affordable, evidencebased

More information

Depression & Alcohol

Depression & Alcohol Depression & Alcohol Black Dog Institute Mission: To advance the understanding and management of the mood disorders through Research Clinical Services Community Support Education Community Support Clinical

More information

Vivitrol/Suboxone. Comparison Study Summary

Vivitrol/Suboxone. Comparison Study Summary Vivitrol/Suboxone Comparison Study Summary Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., & King, J. (2017). Comparative effectiveness of extended-release naltrexone versus

More information

Can you drink alcohol on low dose naltrexone abigail hawk photos nude Exploration of abdominal wound cpt

Can you drink alcohol on low dose naltrexone abigail hawk photos nude  Exploration of abdominal wound cpt Can you drink alcohol on low dose naltrexone abigail hawk photos nude Exploration of abdominal wound cpt how to unlock zte straighttalk phone icd 10 code for chronic elevated ocular pressure Sitemap Alcoholism

More information

Neuroscience of Addiction

Neuroscience of Addiction Neuroscience of Addiction Carlton Erickson, Ph.D. Associate Dean for Research and Graduate Studies Distinguished Professor of Pharmacology Director, Addiction Science Research and Education Center College

More information

Your selected document

Your selected document Your selected document This entry is our analysis of a study added to the Effectiveness Bank and considered particularly relevant to improving outcomes from drug or alcohol interventions in the UK. The

More information

Sustained-release preparations of naltrexone for the treatment of alcohol and opioid dependence: current status

Sustained-release preparations of naltrexone for the treatment of alcohol and opioid dependence: current status Sustained-release preparations of naltrexone for the treatment of alcohol and opioid dependence: current status Linda R. Gowing, Discipline of Pharmacology, University of Adelaide Sarah Larney, National

More information

What Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016

What Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016 What Science Says about Opioid Use Disorder and Its Treatment Perilou Goddard, Ph.D. Department of Psychological Science Northern Kentucky University Examples of Opioids Agonists (activate opioid receptors)

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Nalmefene for reducing alcohol consumption in people with alcohol dependence Draft scope (pre-referral) Draft remit/appraisal

More information

Naltrexone alcoholism medication amazon

Naltrexone alcoholism medication amazon Your browser does not support script The Cure for Alcoholism: Drink Your Way Sober Without Willpower, Abstinence or Discomfort. byroy Eskapa.. I have been taking the medication and following the "program"

More information

Medication for the Treatment of Addiction (MAT)

Medication for the Treatment of Addiction (MAT) Medication for the Treatment of Addiction (MAT) Karol Kaltenbach, PhD Emeritus Professor of Pediatrics Sidney Kimmel Medical College at Thomas Jefferson University Terminology: Words Matter Medication

More information

CSAM-SCAM Fundamentals. Cocaine Basics. Presentation provided by David C. Marsh MD CCSAM

CSAM-SCAM Fundamentals. Cocaine Basics. Presentation provided by David C. Marsh MD CCSAM CSAM-SCAM Fundamentals Cocaine Basics Presentation provided by David C. Marsh MD CCSAM Chronic Illness Relapsing & Remitting in Course Genetic Predisposition Individual Choice a Factor Environmental Influence

More information

Start Low, Go Slow but Treat to Target

Start Low, Go Slow but Treat to Target Start Low, Go Slow but Treat to Target Pharmacotherapy for Depression, Anxiety and At-Risk Alcohol Use in Late Life September 29, 2014 Audio and Control Panel instruction On the phone? Raise your hand

More information

Medications For Alcohol Use Disorder. DATE: October 10, 2017 PRESENTED BY: Alann Weissman-Ward, MD, Addiction Medicine fellow

Medications For Alcohol Use Disorder. DATE: October 10, 2017 PRESENTED BY: Alann Weissman-Ward, MD, Addiction Medicine fellow Medications For Alcohol Use Disorder DATE: October 10, 2017 PRESENTED BY: Alann Weissman-Ward, MD, Addiction Medicine fellow None DISCLOSURES OBJECTIVES Be able to name 4 medications to treat AUD Describe

More information

Pharmacotherapy for Alcohol Dependence

Pharmacotherapy for Alcohol Dependence Evidence Report/Technology Assessment: Number 3 Pharmacotherapy for Alcohol Dependence Summary Under its Evidence-Based Practice Program, the Agency for Health Care Policy and Research (AHCPR) is developing

More information

Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They?

Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They? Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They? Yngvild Olsen, MD, MPH Cecil County Board of Health Workgroup Meeting Elkton, MD October 8, 2013 Objectives

More information

Medication-Assisted Treatment and HIV/AIDS: Aspects in Treating HIV- Infected Drug Users.

Medication-Assisted Treatment and HIV/AIDS: Aspects in Treating HIV- Infected Drug Users. Slide #1 Medication-Assisted Treatment and HIV/AIDS: Aspects in Treating HIV- Infected Drug Users. R. Douglas Bruce, MD, MA, MSc Assistant Professor Yale AIDS Program Medical Director South Central Rehabilitation

More information

Dr. Renner receives honoraria from Reed Medical Education

Dr. Renner receives honoraria from Reed Medical Education Substance Use Disorders Symposium on Men s Health Massachusetts Medical Society June 17, 2010 John A. Renner, Jr., M.D. John A. Renner Jr., MD DISCLOSURES Johnson & Johnson Stock Holder Dr. Renner receives

More information

Opioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine

Opioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine Natural derivatives of opium poppy - Opium - Morphine - Codeine Opioid Agonists Semi synthetics: Derived from chemicals in opium -Diacetylmorphine Heroin - Hydromorphone Synthetics - Oxycodone Propoxyphene

More information

TSM Protocol for Physicians

TSM Protocol for Physicians 1 TSM Protocol for Physicians Dear, fellow physicians: I am a medical physician much like you, probably. I have volunteered to concisely detail how I use The Sinclair Method (TSM), a refined version of

More information

SW OREGON OPIOID SUMMIT. Medication Assisted Recovery for Opioid Use Disorder. Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass

SW OREGON OPIOID SUMMIT. Medication Assisted Recovery for Opioid Use Disorder. Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass SW OREGON OPIOID SUMMIT Medication Assisted Recovery for Opioid Use Disorder Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass Opioid Agonists Mu (μ) receptors stimulated by opioids causing full

More information

Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction

Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary

More information

Medication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs

Medication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs Medication Assisted Treatment Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs Disclosures Employed by the Department of Veterans Affairs

More information

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) دکتر راد گودرزی

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) دکتر راد گودرزی The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) 1 Expanded to include Gambling Disorder Cannabis Withdrawal and Caffeine Withdrawal are new disorders Caffeine Withdrawal

More information

Second of two articles

Second of two articles 1 of 6 2/25/2016 1:27 PM By Tina Rosenberg February 16, 2016 3:21 am Fixes looks at solutions to social problems and why they work. Second of two articles America s drug crisis, which now kills more people

More information

the facts about BUPRENORPHINE for Treatment of Opioid Addiction

the facts about BUPRENORPHINE for Treatment of Opioid Addiction the facts about BUPRENORPHINE for Treatment of Opioid Addiction i I d been shot on the streets, I d been in detox. It was jails, institutions. Death, I knew, was imminent for me so I started my recovery

More information

Opioid dependence: Detoxification

Opioid dependence: Detoxification Opioid dependence: Detoxification What is detoxification? A. Process of removal of toxins from the body? B. Admitting a drug dependent person in a hospital and giving him nutrition? C. Stopping drug use

More information

PHARMACOTHERAPY: INTEGRATING NEW TOOLS INTO PRACTICE

PHARMACOTHERAPY: INTEGRATING NEW TOOLS INTO PRACTICE NAADAC S 2007 LIFE-LONG LEARNING SERIES PHARMACOTHERAPY: INTEGRATING NEW TOOLS INTO PRACTICE Participant s Reference Guide and Workbook presented by: NAADAC, the Association for Addiction Professionals

More information

Vivitrol Vs. Suboxone

Vivitrol Vs. Suboxone Vivitrol Vs. Suboxone Vivitrol - Naltrexone Indicated for opiate dependence and alcohol withdrawal pure antagonist 380mg once every 4 weeks IM Peak plasma concentration in 2 hrs, followed by a second peak

More information

Long term pharmacotherapy for Alcohol Dependence: Anti Craving agents

Long term pharmacotherapy for Alcohol Dependence: Anti Craving agents Long term pharmacotherapy for Alcohol Dependence: Anti Craving agents Myth or Reality? Complete Recovery means a medication-free state True or False? Treatment of Alcoholism Assessment Motivation Alcohol

More information

Buprenorphine and MAT 101

Buprenorphine and MAT 101 Buprenorphine and MAT 101 Why is Medication Assisted Treatment so Important for Recovery? KEN SAFFIER, MD 7 TH ANNUAL INTEGRATION SUMMIT DECEMBER 8, 2016 Disclosures: u Ken Saffier, MD, has nothing to

More information

Alcohol Support Services

Alcohol Support Services Alcohol Alcohol Support Services Washington Recovery Line: 1-866-789-1511 Teen Link: 866-TEENLINK (866-833-6546) Crisis Clinic: 206-461-3222/1-866-427-4747 Alcoholics Anonymous: 206-587-2838 Alanon & Alateen:

More information

Shawn A. Ryan MD, MBA President & Chief Medical Officer Board Certified, Addiction Medicine

Shawn A. Ryan MD, MBA President & Chief Medical Officer Board Certified, Addiction Medicine [Patient-focused, evidence-based addiction treatment] Shawn A. Ryan MD, MBA President & Chief Medical Officer Board Certified, Addiction Medicine BrightView Health All Rights Reserved www.brightviewhealth.com

More information

Opiate Use Disorder and Opiate Overdose

Opiate Use Disorder and Opiate Overdose Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5

More information

Reducing excessive alcohol use and harm in Alaska.

Reducing excessive alcohol use and harm in Alaska. Reducing excessive alcohol use and harm in Alaska. Medication Assisted Treatment for Alcohol Use Disorder: Current Status and Future Directions Barbara J. Mason, Ph.D. Pearson Family Professor Director,

More information

Heroin, Fentanyl and Other Opioids. Steve Hanson

Heroin, Fentanyl and Other Opioids. Steve Hanson Heroin, Fentanyl and Other Opioids Steve Hanson Heroin/Opiates Neurotransmitter-receptor interactions To transmit instructions to cells, neurotransmitters interact with their receptors. receptor neurotransmitters

More information

Medication for the Treatment of Alcohol Use Disorder. Pocket Guide

Medication for the Treatment of Alcohol Use Disorder. Pocket Guide Medication for the Treatment of Alcohol Use Disorder Pocket Guide Medications are underused in the treatment of alcohol use disorder. According to the National Survey on Drug Use and Health, of the estimated

More information

Treatment Approaches for Drug Addiction

Treatment Approaches for Drug Addiction Treatment Approaches for Drug Addiction NOTE: This fact sheet discusses research findings on effective treatment approaches for drug abuse and addiction. If you re seeking treatment, you can call the Substance

More information

Medical Management of Substance Use Disorders: Does research translate to clinical practice

Medical Management of Substance Use Disorders: Does research translate to clinical practice Medical Management of Substance Use Disorders: Does research translate to clinical practice Ashwin A Patkar, MD Professor of Psychiatry & Community & Family Medicine Duke University Medical Center Durham,

More information

The future of pharmacological treatment.

The future of pharmacological treatment. The future of pharmacological treatment. Anne Lingford-Hughes Professor of Addiction Biology, Imperial College. Hon Consultant CNWL NHS Foundation Trust. What substances and when? What Nicotine Alcohol

More information

Overview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone

Overview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone Overview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone Alexander Y. Walley, MD, MSc Associate Professor of Medicine Director, Addiction Medicine Fellowship Boston University

More information

Buprenorphine & Controlled Substance Treatment Agreement

Buprenorphine & Controlled Substance Treatment Agreement Buprenorphine & Controlled Substance Treatment Agreement I agree to accept the following treatment contract for buprenorphine office-based opioid addiction treatment: 1. I will keep my medication in a

More information

Varenicline and Other Pharmacotherapies for Tobacco Dependence

Varenicline and Other Pharmacotherapies for Tobacco Dependence Varenicline and Other Pharmacotherapies for Tobacco Dependence J. Taylor Hays, M.D. Associate Director Nicotine Dependence Center Mayo Clinic 2012 MFMER slide-1 Learning Objectives Understand the mechanism

More information

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION Naltrexone is used as part of a comprehensive programme of treatment against alcoholism to reduce the

More information

Medication Assisted Treatment:

Medication Assisted Treatment: Medication Assisted Treatment: A Training For Multidisciplinary Addiction Professionals Module III Medications 101 Goals for Module III This module reviews the following: Overview of three medications

More information

IDDT Fidelity Action Planning Guidelines

IDDT Fidelity Action Planning Guidelines 1a. Multidisciplinary Team IDDT Fidelity Action Planning Guidelines Definition: All clients targeted for IDDT receive care from a multidisciplinary team. A multi-disciplinary team consists of, in addition

More information

Objectives 11/2/2016. Managing Patients with Substance Abuse. Off Label Disclosure. Steven Shoptaw, PhD Professor Department of Family Medicine, UCLA

Objectives 11/2/2016. Managing Patients with Substance Abuse. Off Label Disclosure. Steven Shoptaw, PhD Professor Department of Family Medicine, UCLA Managing Patients with Substance Abuse Steven Shoptaw, PhD Professor Department of Family Medicine, UCLA Objectives Epidemiology: Substances most likely to be misused in HIV care settings. Diagnostic and

More information

MEDICATION ASSISTED TREATMENTS (MAT) FOR SUBSTANCE USE DISORDERS

MEDICATION ASSISTED TREATMENTS (MAT) FOR SUBSTANCE USE DISORDERS MEDICATION ASSISTED TREATMENTS (MAT) FOR SUBSTANCE USE DISORDERS PHYLLIS RAYNOR, PHD, PMHNP-BC, APRN CLINICAL ASSISTANT PROFESSOR, USC COLLEGE OF NURSING LEARNING OBJECTIVES: Define types of SUD and purposes

More information

THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE. Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept.

THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE. Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept. THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept. Public Health disclosures Dr. Martin has no conflict of interest to disclose.

More information

Naltrexone is an opioid receptor antagonist that reduces

Naltrexone is an opioid receptor antagonist that reduces Review Article The Status of Naltrexone in the Treatment of Alcohol Dependence Specific Effects on Heavy Drinking Helen M. Pettinati, PhD,* Charles P. O Brien, MD, PhD,*y Amanda R. Rabinowitz, BA,* Shoshana

More information

NURSING FOLLOW-UP: NALTREXONE NALTREXONE NURSING FOLLOW-UP VISIT

NURSING FOLLOW-UP: NALTREXONE NALTREXONE NURSING FOLLOW-UP VISIT NURSING FOLLOW-UP: NALTREXONE Provider Name: Provider Signature: Date: NALTREXONE NURSING FOLLOW-UP VISIT Visit type: Scheduled Call-back Walk-in Random call-back Patient Receives: Oral naltrexone Extended-release

More information

6B / Boswell, Grant and Slutske Day 2 August 14, 2008

6B / Boswell, Grant and Slutske Day 2 August 14, 2008 Pharmacological Treatment of Pathological Gambling Jon E. Grant, JD, MD, MPH Associate Professor University of Minnesota School of Medicine Minneapolis, MN Disclosure Information I have the following financial

More information

Appendix F Federation of State Medical Boards

Appendix F Federation of State Medical Boards Appendix F Federation of State Medical Boards Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office SECTION I: PREAMBLE The (name of board) recognizes that the prevalence of addiction

More information

Thaddeus Ulzen MD FRCP(C)FAPA FCGP Professor & Chair, Department of Psychiatry and Behavioral Medicine, Associate Dean for Academic Affairs

Thaddeus Ulzen MD FRCP(C)FAPA FCGP Professor & Chair, Department of Psychiatry and Behavioral Medicine, Associate Dean for Academic Affairs Thaddeus Ulzen MD FRCP(C)FAPA FCGP Professor & Chair, Department of Psychiatry and Behavioral Medicine, Associate Dean for Academic Affairs CCHS/University of Alabama School of Medicine Assessment History

More information

Personality disorders as predictors of treatment outcome in a sample of alcohol dependent veterans with comorbid axis I disorders

Personality disorders as predictors of treatment outcome in a sample of alcohol dependent veterans with comorbid axis I disorders Washington University School of Medicine Digital Commons@Becker Posters 2005: Alcoholism and Comorbidity 2005 Personality disorders as predictors of treatment outcome in a sample of alcohol dependent veterans

More information

9/17/2018 MISSION IMPOSSIBLE: IF YOU CHOOSE TO ACCEPT MISSION JOIN JUSTICE LEAGUE I M POSSIBLE HEPBURN

9/17/2018 MISSION IMPOSSIBLE: IF YOU CHOOSE TO ACCEPT MISSION JOIN JUSTICE LEAGUE I M POSSIBLE HEPBURN MISSION IMPOSSIBLE: IF YOU CHOOSE TO ACCEPT MISSION JOIN JUSTICE LEAGUE I M POSSIBLE HEPBURN 1 ADDICTION PREVENTION & TREATMENT SAVES LIVES According to the Food and Drug Administration s standards for

More information

Medicaid and the Opioid Crisis

Medicaid and the Opioid Crisis Medicaid and the Opioid Crisis Erica Floyd Thomas Bureau Chief of Medicaid Policy Agency for Health Care Administration Presented to: Medical Care Advisory Committee March 20, 2018 1 Florida Medicaid Covers

More information

MAT IN PREGNANCY KAYLA LIFE STAGE 1: ADOLESCENCE LIFE STAGE 2: EARLY ADULTHOOD. family History of addiction. addiction to oral opioids

MAT IN PREGNANCY KAYLA LIFE STAGE 1: ADOLESCENCE LIFE STAGE 2: EARLY ADULTHOOD. family History of addiction. addiction to oral opioids MAT IN PREGNANCY R. COREY WALLER MD, MS PRINCIPAL, HEALTH MANAGEMENT ASSOCIATES FACULTY, INSTITUTE FOR HEALTHCARE INNOVATION (IHI) CHAIR, LEGISLATIVE ADVOCACY COMMITTEE, ASAM KAYLA LIFE STAGE 1: ADOLESCENCE

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice CRIT Program May 2009 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin

More information

Injectable naltrexone (XR-NTX) A RETROSPECTIVE STUDY OF ITS ACCEPTANCE IN A COMMUNITY RECOVERY SETTING BRIANNE FITZGERALD MSN, PMHNP, CARN-AP

Injectable naltrexone (XR-NTX) A RETROSPECTIVE STUDY OF ITS ACCEPTANCE IN A COMMUNITY RECOVERY SETTING BRIANNE FITZGERALD MSN, PMHNP, CARN-AP Injectable naltrexone (XR-NTX) A RETROSPECTIVE STUDY OF ITS ACCEPTANCE IN A COMMUNITY RECOVERY SETTING BRIANNE FITZGERALD MSN, PMHNP, CARN-AP Overview Gavin Foundation Injectable naltrexone Community report

More information

Section 15.3 Long-Term Risks of Alcohol

Section 15.3 Long-Term Risks of Alcohol Objectives Identify five serious physical effects of longterm alcohol abuse. Describe the three stages of alcoholism. List in order three steps taken during recovery from alcoholism. Slide 1 of 25 Myth

More information

Opioid Use Disorders &Medication Treatment

Opioid Use Disorders &Medication Treatment Agency medical director comments Opioid Use Disorders &Medication Treatment Charissa Fotinos, MD, MSc Deputy Chief Medical Officer Washington State Health Care Authority Learning Objectives: 1) Review

More information

Disclosures. Topics of today s training 4/24/2017. Evolving Treads in Medication Assisted Treatment. Christopher J Davis D.O.

Disclosures. Topics of today s training 4/24/2017. Evolving Treads in Medication Assisted Treatment. Christopher J Davis D.O. Evolving Treads in Medication Assisted Treatment Christopher J Davis D.O. CAADC, FASAM Medical Director, The Ranch of Pennsylvania Medical Director, Pyramid Healthcare Diplomate of The American Board of

More information

Child Welfare and MOMS: Building Partnerships to Improve Care

Child Welfare and MOMS: Building Partnerships to Improve Care Child Welfare and MOMS: Building Partnerships to Improve Care Goals Develop collaborative partnerships between MOMS pilot sites and child welfare agencies: Facilitate successful outcomes for clients Jointly

More information

Associate Medical Director of Addiction Medicine, Summa Physicians Inc., Akron, OH Medical Director Esper Treatment Center, Erie, PA Chief Medical

Associate Medical Director of Addiction Medicine, Summa Physicians Inc., Akron, OH Medical Director Esper Treatment Center, Erie, PA Chief Medical Associate Medical Director of Addiction Medicine, Summa Physicians Inc., Akron, OH Medical Director Esper Treatment Center, Erie, PA Chief Medical Officer, Interval Brotherhood Home, Akron, OH Director

More information

Treatment Team Approaches in Substance Abuse Treatment

Treatment Team Approaches in Substance Abuse Treatment Treatment Team Approaches in Substance Abuse Treatment PLANT A SEED AND WATCH IT GROW 2 Substance use disorders span a wide variety of problems arising from substance use, and cover 11 different criteria:

More information

Treatment of Alcoholism in the United States. Evidence-Based Treatment of Alcohol Use Disorder: A Focused Examination of Naltrexone s Role

Treatment of Alcoholism in the United States. Evidence-Based Treatment of Alcohol Use Disorder: A Focused Examination of Naltrexone s Role Treatment of Alcoholism in the United States Evidence-Based Treatment of Alcohol Use Disorder: A Focused Examination of s Role Charles P. O Brien, MD, PhD Professor of Psychiatry University of Pennsylvania

More information

NALTREXONE DAVID CRABTREE, MD, MPH UNIVERSITY OF UTAH HEALTH, 2018

NALTREXONE DAVID CRABTREE, MD, MPH UNIVERSITY OF UTAH HEALTH, 2018 NALTREXONE DAVID CRABTREE, MD, MPH TREATMENT OF OPIOID USE DISORDER (OUD) Majority of people who develop OUD are not receiving treatment Only a small fraction of patients are offered treatment with medications

More information

Depression often comorbid with alcohol dependence 1.6x higher rate of alcohol dependence in depressed subjects Depressed subjects with alcohol

Depression often comorbid with alcohol dependence 1.6x higher rate of alcohol dependence in depressed subjects Depressed subjects with alcohol Lindsay French PGY3 Depression often comorbid with alcohol dependence 1.6x higher rate of alcohol dependence in depressed subjects Depressed subjects with alcohol dependence have complicated course of

More information